Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma-Reference-Cited by-同舟云学术

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

Published:2010-08-20 Issue:9 Volume:101 Page:2059-2064
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:

Author:

Ohmachi Ken,Ando Kiyoshi,Ogura Michinori,Uchida Toshiki,Itoh Kuniaki,Kubota Nobuko,Ishizawa Kenichi,Yamamoto Joji,Watanabe Takashi,Uike Naokuni,Choi Ilseung,Terui Yasuhito,Usuki Kensuke,Nagai Hirokazu,Uoshima Nobuhiko,Tobinai Kensei,

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2010.01635.x/fullpdf

Reference28 articles.

1. Global cancer statistics, 2002, updated as of October 27, 2009;Parkin;CA Cancer J Clin,2009

2. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas;Horning;Semin Oncol,1993

3. Karnofsky memorial lecture. The low-grade non-Hodgkin’s lymphomas: challenges and opportunities;Rosenberg;J Clin Oncol,1985

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lymphocyte recovery after bendamustine therapy in patients with mantle cell lymphoma. Results of a retrospective analysis and prognostic impact in the CAR-T era;Annals of Hematology;2024-08-30

2. Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review;Journal of Blood Medicine;2024-05

3. Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL;Cancer Treatment Reviews;2024-03

4. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials;Frontiers in Immunology;2022-11-11

5. Time to Onset of Bendamustine-associated Skin Damage Using the Spontaneous Reporting System;Anticancer Research;2022-04-30